BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...is part of a growing wave of China biotechs led by academics; the subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...RemeGen is part of growing wave of China biotechs led by academics; the subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...different strategies, including endpoint selection and focusing on proven pathways. RemeGen is a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
...molecule cenerimod from Idorsia Ltd. (SIX:IDIA) and fusion protein telitacicept from the RemeGene subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...has gained CHF0.52 to CHF23.70 since reporting the data. Chinese drugmaker RemeGen, a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
Items per page:
1 - 5 of 5
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...is part of a growing wave of China biotechs led by academics; the subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...RemeGen is part of growing wave of China biotechs led by academics; the subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...different strategies, including endpoint selection and focusing on proven pathways. RemeGen is a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
...molecule cenerimod from Idorsia Ltd. (SIX:IDIA) and fusion protein telitacicept from the RemeGene subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...has gained CHF0.52 to CHF23.70 since reporting the data. Chinese drugmaker RemeGen, a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd....
Items per page:
1 - 5 of 5